Journal
CELL CALCIUM
Volume 103, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ceca.2022.102554
Keywords
Prostate Cancer; Androgen Deprivation Therapy; CaV1.3; Store operated calcium entry; CACNA1D; Aberrant Intracellular Calcium; Abbreviations; Androgen Deprivation Therapy (ADT); Androgen Receptor (AR); Calcium (Ca2+); Calcium Channel Blocker (CCB); Castrate Resistant Prostate Cancer (CRPC); Cellular Invasion and Migration (CIM); Colony Formation Assay (CFA); Cytosolic Calcium (Cac2+); Glyceraldehyde 3-phosphate dehydrogenase (GAPDH); Immunofluorescence (IF); Intracellular Calcium (Cai2+); Log2 fold-change (LogFC); Multiple Comparison Test (MCT); Principal Components Analysis (PCA); Prostate Cancer (PCa); Quality Control (QC); Thapsigargin (Tg); Tumour Microarrays (TMA); siRNA CaV1.3 (SiCaV1.3); SiRNA Control (sictr); Short Tandem Array (STR); Store Operated Current (SOC)
Categories
Funding
- Dublin City University School of Nursing, Psychotherapy and Community Health PhD studentship [201618]
- Irish Research Council (IRC) Government of Ireland [GOIPG/2018/373]
- Ulysses Award [2018] - IRC
- Ulysses Award [2018] - ministeres de l'Europe et des affaires etrangeres et de l'enseignement superieur, de la recherche et de l'innovation
Ask authors/readers for more resources
Research has found that the voltage gated calcium channel CaV1.3 is increased in prostate cancer patients undergoing androgen deprivation therapy (ADT). Increased CaV1.3 isoforms promote resistance to ADT by upregulating store operated calcium entry (SOCE) and enhancing the proliferation and survival of castrate resistant prostate cancer cells.
Androgen deprivation therapy (ADT) is the main treatment for advanced prostate cancer (PCa) but resistance results in progression to terminal castrate resistant PCa (CRPC), where there is an unmet therapeutic need. Aberrant intracellular calcium (Ca-i(2+)) is known to promote neoplastic transformation and treatment resistance. There is growing evidence that voltage gated calcium channel (VGCC) expression is increased in cancer, particularly CACNA1D/CaV1.3 in CRPC. The aim of this study was to investigate if increased CaV1.3 drives resistance to ADT and determine its associated impact on Ca-i(2+) and cancer biology. Bioinformatic analysis revealed that CACNA1D gene expression is increased in ADT treated PCa patients. This was corroborated in both in vivo LNCaP xenograft mouse and in vitro PCa cell line models, which demonstrated a significant increase in CaV1.3 protein expression following ADT with bicalutamide. Expression was found to be of a shortened 170kDa CaV1.3 isoform associated with plasma and intracellular membranes, which failed to induce calcium influx following membrane depolarisation. Instead, under ADT CaV1.3 mediated a rise in basal cytosolic calcium and an increase in store operated calcium entry (SOCE). This mechanism was found to promote the proliferation and survival of ADT resistant CRPC cells. Overall, this study demonstrates for the first time in PCa that under ADT specific CaV1.3 isoforms promote an upregulation of SOCE which contributes to treatment resistance and CRPC biology. Thus, this novel oncochannel represents a target for therapeutic development to improve PCa patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
